Pyoderma gangrenosum and Behcet's-like disease induced by secukinumab: a paradoxical drug reaction

Review Dermatology

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

Fabrizio Martora et al.

Summary: To date, adalimumab is the only approved biotechnology drug for managing hidradenitis suppurativa (HS), but its efficacy in real-life practice varies. This review analyzes the current evidence on the use of biologics in HS, particularly adalimumab, secukinumab, ustekinumab, and ixekizumab. While the results are promising, more studies are needed. The armamentarium of drugs for HS management is expanding, allowing for personalized treatment approaches to minimize adverse events.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2023)

添加到收藏夹

Letter Dermatology

Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review

Akihiro Orita et al.

Summary: This article presents a case of pyoderma gangrenosum (PG) caused by secukinumab and successfully treated with risankizumab. The literature review indicates that IL-23 may play a significant role in the pathogenesis of PG, suggesting IL-23-targeting therapies as a potential treatment option for PG.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

添加到收藏夹

Review Dermatology

The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition

Francesco Messina et al.

Summary: As aberrant IL-17 signaling is crucial in psoriasis pathogenesis, biologic agents targeting this pathway have emerged as important therapies. However, these treatments may lead to various dermatological manifestations, with paradoxical psoriasis and atopic-like eczema being the most common.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Article Dermatology

Neutrophilic Dermatoses: a Clinical Update

Emma H. Weiss et al.

Summary: Neutrophilic dermatoses are characterized by sterile neutrophilic infiltrates and have diverse cutaneous and extracutaneous manifestations, often associated with significant morbidity and mortality. Recent studies have shed light on the complex pathogenesis of these disorders, involving abnormal neutrophil function, inflammasome activation, malignant transformation, and genetic predisposition. Diagnostic and therapeutic advancements are identifying new roles for biologic and targeted anti-inflammatory therapies in the management of neutrophilic dermatoses.

CURRENT DERMATOLOGY REPORTS (2022)

添加到收藏夹

Letter Dermatology